Bristol-Myers Squibb Company
CAMK2D ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
Last updated:
Abstract:
The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.
Status:
Application
Type:
Utility
Filling date:
9 Jun 2021
Issue date:
9 Dec 2021